BACKGROUND: The effect of early versus deferred antiretroviral treatment (ART) on plasma concentration of lipopolysaccharide (LPS) and host LPS-binding molecules in human immunodeficiency virus (HIV)-infected infants up to 1 year of age was investigated. METHODS: We evaluated 54 perinatally HIV-infected and 22 HIV-exposed uninfected infants (controls) at the first and second semester of life. All HIV-infected infants had a baseline CD4 of ≥ 25%, participated in the Comprehensive International Program of Research on AIDS Children with HIV Early Antiretroviral Therapy trial in South Africa, and were randomized in the following groups: group 1 (n = 20), ART deferred until CD4 < 25% or severe HIV disease; and group 2 (n = 34), ART initiation within 6 to 12 weeks of age. LPS, endotoxin-core antibodies, soluble CD14 (sCD14), and LPS-binding protein (LBP) were measured in cryopreserved plasma. T-cell activation was measured in fresh whole blood. RESULTS: At the first semester, LPS concentration was higher in HIV-infected infants than in controls; sCD14, LBP, and T-cell activation were higher in group 1 than in group 2 and controls. Although LPS was not correlated with study variables, viral load was positively associated with sCD14, LBP, or endotoxin-core antibodies. At the second semester, LPS was not detectable and elevated host LPS-control molecules values were sustained in all groups and in conjunction with ART in all HIV-infected infants. CONCLUSIONS: Although plasma concentration of LPS was higher in perinatally HIV-infected infants 0 to 6 months of age than in controls independent of ART initiation strategy, concentration of LPS-control molecules was higher in infants with deferred ART, suggesting the presence of increased microbial translocation in HIV-infected infants with sustained early viral replication.
RCT Entities:
BACKGROUND: The effect of early versus deferred antiretroviral treatment (ART) on plasma concentration of lipopolysaccharide (LPS) and host LPS-binding molecules in humanimmunodeficiency virus (HIV)-infectedinfants up to 1 year of age was investigated. METHODS: We evaluated 54 perinatally HIV-infected and 22 HIV-exposed uninfected infants (controls) at the first and second semester of life. All HIV-infectedinfants had a baseline CD4 of ≥ 25%, participated in the Comprehensive International Program of Research on AIDSChildren with HIV Early Antiretroviral Therapy trial in South Africa, and were randomized in the following groups: group 1 (n = 20), ART deferred until CD4 < 25% or severe HIV disease; and group 2 (n = 34), ART initiation within 6 to 12 weeks of age. LPS, endotoxin-core antibodies, soluble CD14 (sCD14), and LPS-binding protein (LBP) were measured in cryopreserved plasma. T-cell activation was measured in fresh whole blood. RESULTS: At the first semester, LPS concentration was higher in HIV-infectedinfants than in controls; sCD14, LBP, and T-cell activation were higher in group 1 than in group 2 and controls. Although LPS was not correlated with study variables, viral load was positively associated with sCD14, LBP, or endotoxin-core antibodies. At the second semester, LPS was not detectable and elevated host LPS-control molecules values were sustained in all groups and in conjunction with ART in all HIV-infectedinfants. CONCLUSIONS: Although plasma concentration of LPS was higher in perinatally HIV-infectedinfants 0 to 6 months of age than in controls independent of ART initiation strategy, concentration of LPS-control molecules was higher in infants with deferred ART, suggesting the presence of increased microbial translocation in HIV-infectedinfants with sustained early viral replication.
Authors: M de Martino; P A Tovo; L Galli; C Gabiano; S Cozzani; C Gotta; G Scarlatti; A Fiocchi; P Cocchi; P Marchisio Journal: J Pediatr Date: 1991-11 Impact factor: 4.406
Authors: J A Windsor; K C Fearon; J A Ross; G R Barclay; E Smyth; I Poxton; O J Garden; D C Carter Journal: Br J Surg Date: 1993-08 Impact factor: 6.939
Authors: E Kivilaakso; V V Valtonen; M Malkamäki; A Palmu; T Schröder; P Nikki; P H Mäkelä; M Lempinen Journal: Gut Date: 1984-10 Impact factor: 23.059
Authors: E A Frey; D S Miller; T G Jahr; A Sundan; V Bazil; T Espevik; B B Finlay; S D Wright Journal: J Exp Med Date: 1992-12-01 Impact factor: 14.307
Authors: E Hailman; H S Lichenstein; M M Wurfel; D S Miller; D A Johnson; M Kelley; L A Busse; M M Zukowski; S D Wright Journal: J Exp Med Date: 1994-01-01 Impact factor: 14.307
Authors: Rafael Fernandez-Botran; Swati Joshi-Barve; Smita Ghare; Shirish Barve; Mary Young; Michael Plankey; Jose Bordon Journal: J Interferon Cytokine Res Date: 2014-06-23 Impact factor: 2.607
Authors: Sarah F Benki-Nugent; Ira Martopullo; Tony Laboso; Nancy Tamasha; Dalton C Wamalwa; Kenneth Tapia; Agnes Langat; Elizabeth Maleche-Obimbo; Christina M Marra; Paul Bangirana; Michael J Boivin; Grace C John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: Athena P Kourtis; Chris C Ibegbu; Jeffrey Wiener; Caroline C King; Gerald Tegha; Deborah Kamwendo; Jacob Kumwenda; Surinder P Kaur; Valerie Flax; Sascha Ellington; Zebrone Kacheche; Dumbani Kayira; Charles Chasela; Charles van der Horst; Denise J Jamieson Journal: J Infect Dis Date: 2013-05-17 Impact factor: 5.226